Resonance Health Limited (ASX: RHT) - Share Price
- Current share price for RHT : $0.074
Resonance Health Limited (RHT) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a Company engaged in development and commercialisation of software-as-medical-device (‘SaMD') technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment.
RHT General Information +
| ASX Code | RHT |
| Website | http://www.resonancehealth.com |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | 35 |
| RHT Share Price | $0.074 |
| Day High | $0.077 |
| Day Low | $0.074 |
| Last Close | $0.074 |
| RHT Share Price Movement | - ( No change ) |
Prices as at 16:40, 29 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Resonance Health Limited (RHT) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Resonance Health Limited (RHT) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Resonance Health Limited (RHT) price-sensitive announcements
RHT - Liver Fibrosis Device Webinar Presentation
Resonance Health announced a 28 October 2026 investor webinar to discuss preliminary resul
Resonance Health Limited (RHT)
28 Oct 2026 | 12:36 PM
28 Oct 2026 | 12:36 PM
RHT - Investor Presentation Liver Fibrosis Device & Capital Raise
Resonance Health’s October 2026 investor presentation outlines a $6.0 million placement at
Resonance Health Limited (RHT)
27 Oct 2026 | 9:57 AM
27 Oct 2026 | 9:57 AM
RHT - $6.0 Million Placement Oversubscribed
Resonance Health announced an oversubscribed $6.0 million placement to institutional, prof
Resonance Health Limited (RHT)
27 Oct 2026 | 9:57 AM
27 Oct 2026 | 9:57 AM
RHT - Liver Fibrosis Device - EPoC Study Results
Resonance Health announced preliminary extended proof-of-concept (EPoC) results from the D
Resonance Health Limited (RHT)
27 Oct 2026 | 9:56 AM
27 Oct 2026 | 9:56 AM
Resonance Health Limited (RHT) Recent ASX Announcements
RHT Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | $1.51 | $0.30 | -181.60% | 13.90 | 0.00 | 0.00% | 0.0% |
| 2025A | -$1.73 | -$0.40 | -141.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | $4.17 | $0.90 | -668.80% | 6.80 | 0.00 | 0.00% | 0.0% |
RHT Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Cochlear Limited (COH) | $9,156M | -0.3136 | 0.2540 | 0.0785 | 34.0840 | 27.1802 | 25.2021 | 2.46% | 2.56% | 2.79% |
| Fisher & Paykel Healthcare Corporation Limited (FPH) | $22,248M | 0.1388 | 0.1452 | 0.1573 | 57.1904 | 49.9406 | 43.1538 | 1.15% | 1.24% | 1.38% |
| Imricor Medical Systems Inc (IMR) | $481M | -0.4254 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Resonance Health Limited (RHT) | $36M | -1.8158 | 0.0000 | 0.0000 | 24.1935 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| ResMed Inc. (RMD) | $20,029M | 9.5922 | 0.1012 | 0.0991 | 22.8102 | 20.7147 | 18.8476 | 1.02% | 1.11% | 1.20% |
RHT Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.26 | 23.90 | 3.18 | 0.00 |
| Market | 0.30 | 13.20 | 1.03 | 0.74 |
| Sector | 0.72 | 21.80 | 1.76 | 2.45 |
RHT Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Andrew Duncan Harrison | Chief Executive Officer, Managing Director | 1 Oct 2025 |
| Mr Mitchell MacDonald Wells | Company Secretary, Non Executive Director | 28 Feb 2018 |
| Dr David Fuller | Non-Executive Director | 28 Apr 2026 |
| Mr Simon Panton | Non-Executive Director | 5 Oct 2009 |
| Mr Michael Karl-Gerhard Sistenich | Non-Executive Director | 28 Apr 2026 |
| Dr Travis Baroni | Non-Executive Director | 25 Nov 2016 |
| Mr Aaron Brinkworth | Non-Executive Director, Non-Executive Chairman | 27 Mar 2023 |
Resonance Health Limited (RHT) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 13 Jul 2026 | PANTON, Simon | Buy | Indirect Shares | 1,640,824 | $0.045 | $73,837.000 |
| 22 May 2026 | FULLER, David | Buy | Indirect Shares | 98,701 | $0.040 | $3,962.990 |
| 27 Mar 2026 | PANTON, Simon | Buy | Indirect Shares | 2,650,000 | $0.040 | $106,000.000 |
See all changes in directors' interest & trades for Resonance Health Limited (RHT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
RHT Management
| Name | Position |
|---|---|
| Benjamin Carruthers | Chief Financial Officer |
RHT Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Resonance Health Limited (RHT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 72,546,350 (15.20%) | Southam Investments 2003 P/L (Warwickshire Investments A/C) |
| 35,928,598 (7.50%) | SG Hiscock & Company Limited |
RHT Calendar of Events
| Date | Event |
|---|---|
| 27 August 2027 | Report (Annual) |
| 27 August 2027 | Report (Prelim) |
| 26 February 2027 | Report (Interim) |
| 19 November 2026 | AGM |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
